Full-Time
Confirmed live in the last 24 hours
Develops cell therapy for chronic kidney disease
Senior
Winston-Salem, NC, USA
ProKidney develops a cell therapy called rilparencel aimed at preserving kidney function in patients with Chronic Kidney Disease (CKD), potentially delaying or eliminating the need for dialysis. The company is in the late stages of clinical trials, with early data suggesting that rilparencel may effectively maintain kidney function. ProKidney differentiates itself by focusing specifically on CKD, addressing a significant need in the healthcare market. The goal is to provide a viable alternative to dialysis, improving the quality of life for millions of CKD patients.
Company Stage
IPO
Total Funding
$559.3M
Headquarters
Winston-Salem, North Carolina
Founded
2015
Help us improve and share your feedback! Did you find this helpful?